DE10036742A1 - Vorrichtung zur Behandlung von Immunerkrankungen - Google Patents

Vorrichtung zur Behandlung von Immunerkrankungen

Info

Publication number: DE10036742A1
Authority: DE; Germany
Prior art keywords: antigens; blood; line; immune; immunoglobulins
Prior art date: 2000-07-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

DE10036742A

Other languages

German (de)

English (en)

Inventor

Torsten Matthias

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

AESKU LAB DIAGNOSTIKA

Original Assignee

AESKU LAB DIAGNOSTIKA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-27

Filing date

2000-07-27

Publication date

2002-02-21

2000-07-27 Application filed by AESKU LAB DIAGNOSTIKA filed Critical AESKU LAB DIAGNOSTIKA

2000-07-27 Priority to DE10036742A priority Critical patent/DE10036742A1/de

2001-07-27 Priority to DE10193004T priority patent/DE10193004D2/de

2001-07-27 Priority to PCT/DE2001/002884 priority patent/WO2002009793A1/fr

2001-07-27 Priority to AU2001278407A priority patent/AU2001278407A1/en

2002-02-21 Publication of DE10036742A1 publication Critical patent/DE10036742A1/de

Status Withdrawn legal-status Critical Current

Links

208000026278 immune system disease Diseases 0.000 title claims abstract description 12
239000000427 antigen Substances 0.000 claims abstract description 37
102000036639 antigens Human genes 0.000 claims abstract description 37
108091007433 antigens Proteins 0.000 claims abstract description 37
210000004369 blood Anatomy 0.000 claims abstract description 21
239000008280 blood Substances 0.000 claims abstract description 21
108060003951 Immunoglobulin Proteins 0.000 claims abstract description 20
102000018358 immunoglobulin Human genes 0.000 claims abstract description 20
229940072221 immunoglobulins Drugs 0.000 claims abstract description 15
208000023275 Autoimmune disease Diseases 0.000 claims description 9
239000002245 particle Substances 0.000 claims description 9
201000010099 disease Diseases 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
238000000502 dialysis Methods 0.000 claims description 7
206010020751 Hypersensitivity Diseases 0.000 claims description 5
230000007815 allergy Effects 0.000 claims description 5
230000001506 immunosuppresive effect Effects 0.000 claims description 5
108020004414 DNA Proteins 0.000 claims description 4
102000053602 DNA Human genes 0.000 claims description 4
108091005804 Peptidases Proteins 0.000 claims description 4
102000035195 Peptidases Human genes 0.000 claims description 4
208000026935 allergic disease Diseases 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
239000004816 latex Substances 0.000 claims description 3
229920000126 latex Polymers 0.000 claims description 3
235000019833 protease Nutrition 0.000 claims description 3
210000002966 serum Anatomy 0.000 claims description 3
102000006947 Histones Human genes 0.000 claims description 2
108010033040 Histones Proteins 0.000 claims description 2
108010047956 Nucleosomes Proteins 0.000 claims description 2
239000004793 Polystyrene Substances 0.000 claims description 2
108020004682 Single-Stranded DNA Proteins 0.000 claims description 2
102000005890 Spectrin Human genes 0.000 claims description 2
108010019965 Spectrin Proteins 0.000 claims description 2
206010052779 Transplant rejections Diseases 0.000 claims description 2
239000011324 bead Substances 0.000 claims description 2
239000011521 glass Substances 0.000 claims description 2
239000012510 hollow fiber Substances 0.000 claims description 2
229960003444 immunosuppressant agent Drugs 0.000 claims description 2
239000003018 immunosuppressive agent Substances 0.000 claims description 2
210000001623 nucleosome Anatomy 0.000 claims description 2
229920002223 polystyrene Polymers 0.000 claims description 2
108020003175 receptors Proteins 0.000 claims description 2
238000002560 therapeutic procedure Methods 0.000 claims description 2
239000000654 additive Substances 0.000 claims 2
239000004365 Protease Substances 0.000 claims 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
239000000969 carrier Substances 0.000 claims 1
239000007795 chemical reaction product Substances 0.000 claims 1
210000003734 kidney Anatomy 0.000 claims 1
239000011159 matrix material Substances 0.000 claims 1
239000000741 silica gel Substances 0.000 claims 1
229910002027 silica gel Inorganic materials 0.000 claims 1
239000000126 substance Substances 0.000 description 15
210000000987 immune system Anatomy 0.000 description 10
210000004027 cell Anatomy 0.000 description 9
230000028993 immune response Effects 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000001717 pathogenic effect Effects 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
230000000172 allergic effect Effects 0.000 description 3
239000012876 carrier material Substances 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000008105 immune reaction Effects 0.000 description 3
230000006058 immune tolerance Effects 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
201000000596 systemic lupus erythematosus Diseases 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
241000894006 Bacteria Species 0.000 description 2
208000009137 Behcet syndrome Diseases 0.000 description 2
108050006400 Cyclin Proteins 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 2
206010042742 Sympathetic ophthalmia Diseases 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
230000000340 anti-metabolite Effects 0.000 description 2
210000000612 antigen-presenting cell Anatomy 0.000 description 2
229940100197 antimetabolite Drugs 0.000 description 2
239000002256 antimetabolite Substances 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000470 constituent Substances 0.000 description 2
230000037029 cross reaction Effects 0.000 description 2
239000000824 cytostatic agent Substances 0.000 description 2
230000001085 cytostatic effect Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
108010006620 fodrin Proteins 0.000 description 2
239000012634 fragment Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
210000003630 histaminocyte Anatomy 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
244000005700 microbiome Species 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
206010028417 myasthenia gravis Diseases 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
230000035515 penetration Effects 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
241000566113 Branta sandvicensis Species 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
208000027932 Collagen disease Diseases 0.000 description 1
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
102000003915 DNA Topoisomerases Human genes 0.000 description 1
108090000323 DNA Topoisomerases Proteins 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
102100026060 Exosome component 10 Human genes 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
208000024869 Goodpasture syndrome Diseases 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
101001055976 Homo sapiens Exosome component 10 Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000003814 Interleukin-10 Human genes 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
208000003456 Juvenile Arthritis Diseases 0.000 description 1
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
208000003250 Mixed connective tissue disease Diseases 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
201000011152 Pemphigus Diseases 0.000 description 1
208000031845 Pernicious anaemia Diseases 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
208000033464 Reiter syndrome Diseases 0.000 description 1
102000002278 Ribosomal Proteins Human genes 0.000 description 1
108010000605 Ribosomal Proteins Proteins 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
206010043784 Thyroiditis subacute Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
108091026838 U1 spliceosomal RNA Proteins 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
206010047112 Vasculitides Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
102000034337 acetylcholine receptors Human genes 0.000 description 1
208000037855 acute anterior uveitis Diseases 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
229940038481 bee pollen Drugs 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000002230 centromere Anatomy 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
229960002173 citrulline Drugs 0.000 description 1
235000013477 citrulline Nutrition 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
229960004544 cortisone Drugs 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
230000007123 defense Effects 0.000 description 1
238000009795 derivation Methods 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
230000009266 disease activity Effects 0.000 description 1
ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
230000000694 effects Effects 0.000 description 1
101150023929 egg gene Proteins 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000012041 food component Nutrition 0.000 description 1
239000005417 food ingredient Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229940046528 grass pollen Drugs 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
230000008004 immune attack Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229940076144 interleukin-10 Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
210000002415 kinetochore Anatomy 0.000 description 1
229960000681 leflunomide Drugs 0.000 description 1
VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
201000008350 membranous glomerulonephritis Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
238000000034 method Methods 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000036473 myasthenia Effects 0.000 description 1
229940014456 mycophenolate Drugs 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
201000003631 narcolepsy Diseases 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
231100000255 pathogenic effect Toxicity 0.000 description 1
201000001976 pemphigus vulgaris Diseases 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
208000002574 reactive arthritis Diseases 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
238000004064 recycling Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000007363 regulatory process Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
108010010318 streptococcal M protein Proteins 0.000 description 1
201000007497 subacute thyroiditis Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0415—Plasma
- A61M2202/0417—Immunoglobulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Heart & Thoracic Surgery (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Hematology (AREA)
Anesthesiology (AREA)
Cell Biology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biodiversity & Conservation Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Transplantation (AREA)
Pharmacology & Pharmacy (AREA)
Cardiology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
External Artificial Organs (AREA)
Medicinal Preparation (AREA)

DE10036742A 2000-07-27 2000-07-27 Vorrichtung zur Behandlung von Immunerkrankungen Withdrawn DE10036742A1 (de)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
DE10036742A DE10036742A1 (de)	2000-07-27	2000-07-27	Vorrichtung zur Behandlung von Immunerkrankungen
DE10193004T DE10193004D2 (de)	2000-07-27	2001-07-27	Vorrichtung zur Behandlung von Immunerkrankungen
PCT/DE2001/002884 WO2002009793A1 (fr)	2000-07-27	2001-07-27	Dispositif de traitement de maladies du systeme immunitaire
AU2001278407A AU2001278407A1 (en)	2000-07-27	2001-07-27	Device for treating immune diseases

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10036742A DE10036742A1 (de)	2000-07-27	2000-07-27	Vorrichtung zur Behandlung von Immunerkrankungen

Publications (1)

Publication Number	Publication Date
DE10036742A1 true DE10036742A1 (de)	2002-02-21

Family

ID=7650487

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE10036742A Withdrawn DE10036742A1 (de)	2000-07-27	2000-07-27	Vorrichtung zur Behandlung von Immunerkrankungen
DE10193004T Expired - Fee Related DE10193004D2 (de)	2000-07-27	2001-07-27	Vorrichtung zur Behandlung von Immunerkrankungen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DE10193004T Expired - Fee Related DE10193004D2 (de)	2000-07-27	2001-07-27	Vorrichtung zur Behandlung von Immunerkrankungen

Country Status (3)

Country	Link
AU (1)	AU2001278407A1 (fr)
DE (2)	DE10036742A1 (fr)
WO (1)	WO2002009793A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2842746A1 (fr) *	2002-07-26	2004-01-30	Univ Nancy 1 Henri Poincare	Colonne d'immunoaffinite pour epuration d'anticorps comportant des microparticules polymeres encapsulant des antigenes associes a des phospholipides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0313378A2 (fr) *	1987-10-23	1989-04-26	Imre Corporation	Méthodes et compositions pour l'elimination temporaire d'anticorps immuns humoraux
WO1989004675A1 (fr) *	1987-11-20	1989-06-01	Creative Biomolecules, Inc.	Elimination selective de complexes immuns
WO1999036110A1 (fr) *	1998-01-20	1999-07-22	Mitra Medical Technology Ab	Appareil utilisable pour extraire des elements, notamment des anticorps exogenes, presents dans du sang ou du plasma sanguin
DE19538641C2 (de) *	1995-10-05	2000-09-21	Privates Inst Bioserv Gmbh	Patientenspezifische Immunadsorber für die extrakorporale Apherese und Verfahren für deren Herstellung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0103184B1 (fr) *	1982-08-12	1990-01-17	Kanegafuchi Chemical Industry Co., Ltd.	Activation de terpolymères biocompatibles par des agents biologiques dont les compléments à fixer sont des effecteurs pathologiques
DE3664729D1 (en) *	1985-04-09	1989-09-07	Terumo Corp	Immunoglobulin adsorbent and adsorption apparatus
EP0661980B1 (fr) *	1991-08-23	2003-02-19	Alberta Research Council	Procedes et compositions d'attenuation de rejet de xenogrephe induit par les anticorps chez les receveurs humains
US5868936A (en) *	1996-06-20	1999-02-09	Baxter International Inc.	Affinity membrane system and method of using same
AU2408700A (en) *	1999-01-11	2000-08-01	Baxter International Inc.	Method and apparatus for selectively removing xenoreactive antibodies from blood, serum or plasma

2000
- 2000-07-27 DE DE10036742A patent/DE10036742A1/de not_active Withdrawn
2001
- 2001-07-27 WO PCT/DE2001/002884 patent/WO2002009793A1/fr not_active Ceased
- 2001-07-27 AU AU2001278407A patent/AU2001278407A1/en not_active Abandoned
- 2001-07-27 DE DE10193004T patent/DE10193004D2/de not_active Expired - Fee Related

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0313378A2 (fr) *	1987-10-23	1989-04-26	Imre Corporation	Méthodes et compositions pour l'elimination temporaire d'anticorps immuns humoraux
WO1989004675A1 (fr) *	1987-11-20	1989-06-01	Creative Biomolecules, Inc.	Elimination selective de complexes immuns
DE19538641C2 (de) *	1995-10-05	2000-09-21	Privates Inst Bioserv Gmbh	Patientenspezifische Immunadsorber für die extrakorporale Apherese und Verfahren für deren Herstellung
WO1999036110A1 (fr) *	1998-01-20	1999-07-22	Mitra Medical Technology Ab	Appareil utilisable pour extraire des elements, notamment des anticorps exogenes, presents dans du sang ou du plasma sanguin

Also Published As

Publication number	Publication date
WO2002009793A1 (fr)	2002-02-07
AU2001278407A1 (en)	2002-02-13
DE10193004D2 (de)	2002-10-31
WO2002009793A8 (fr)	2002-04-18

Publication	Publication Date	Title
DE69222303T2 (de)	1998-01-22	Kationisierte antikörper gegen intrazelluläre eiweisse
Degos et al.	2013	Bone fracture exacerbates murine ischemic cerebral injury
Fischer et al.	2019	Exogenous activation of tumor necrosis factor receptor 2 promotes recovery from sensory and motor disease in a model of multiple sclerosis
EP1163004B1 (fr)	2003-03-05	Immuno-adsorbants pour le traitement de la septicemie
DE19505287A1 (de)	1995-08-24	Zusammensetzung und Verfahren zur Prävention und Behandlung von Entzündungen mit Immunglobulin A
Miyake et al.	1989	Reactions of S-100-positive glia after injury of mouse cerebral cortex
DE19916085A1 (de)	2000-05-04	Verfahren zur Herstellung eines antiviralen Mittels
DE69725754T2 (de)	2004-08-19	Eingekapselte Antikörper-produzierende Zellen
DE10036742A1 (de)	2002-02-21	Vorrichtung zur Behandlung von Immunerkrankungen
DE102008014880A1 (de)	2009-09-17	Antientzündliches Polypeptid
DE102004042894A1 (de)	2006-03-02	Verwendung von Blockern der NKG2D-Rezeptor-/NKG2D-Liganden-Interaktion bei Autoimmunerkrankungen
Miyakawa et al.	1976	Late changes in human sural nerves in Minamata disease and in nerves of rats with experimental organic mercury poisoning
DE2732437B2 (de)	1979-02-01	Wasserunlösliches Haptoglobinpräparat und Verfahren zu seiner Herstellung
EP1141018A2 (fr)	2001-10-10	Peptides du recepteur at1 et son utilisation en cas de preeclampsie et d'hypertension maligne
EP1162276A2 (fr)	2001-12-12	Molécules d' ARN messager à utiliser comme indicateurs de l'état d'activité et de fonctionnement des lymphocytes-T
EP0951481B1 (fr)	2004-11-24	Utilisation de substance a effet immunomodulateur pour le traitement de la sclerose lateral amyotrophique
Nishihara et al.	1981	Masugi nephritis produced by the antiserum to heterologous glomerular basement membrane: I. Results in mice
EP2329262A2 (fr)	2011-06-08	Système de filtrage permettant l'administration extra-corporelle de granulocytes polymorphonucléaires (leucocytes polymorphonucléaires - pmn) activés
DE10038722C2 (de)	2002-07-25	Verfahren zur Reduzierung von spezifischen Immunreaktionen
DE19711795C2 (de)	2001-03-08	Verwendung von Cyclosporin für die Behandlung von Myokardinfarkten und deren Folgen
DE10138550A1 (de)	2003-02-20	Verwendung von TIMP-1 als Immunsuppressivum
DE102008019916A1 (de)	2009-10-29	Verfahren zur Eliminierung von langlebigen Plasmazellen
EP0889053A2 (fr)	1999-01-07	Utilisations des préparations à base de BK-RiV, procédé de leur production, et les protéines contenues dans celles-ci
DE4409513C1 (de)	1995-10-19	Verwendung von anti-TNF-Antikörpern als Arzneimittel zur Behandlung von Erkrankungen mit einem erhöhten Interleukin-6 Serumspiegel
Cole et al.	2022	Einblicke in die Pathogenese des bullösen Pemphigoids: Die Rolle komplementunabhängiger Mechanismen

Legal Events

Date	Code	Title	Description
2002-02-21	OP8	Request for examination as to paragraph 44 patent law
2002-09-26	8143	Lapsed due to claiming internal priority